Isomannide derivatives as inhibitors of soluble epoxide hydrolase

US9540391B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Katrin Lorenz · Frankfurt am Main, DE
• Kristin Breitschopf · Frankfurt am Main, DE
• Hartmut Strobel · Liederbach, DE
• Maria MENDEZ-PEREZ · Frankfurt am Main, DE
• Li Wang · Frankfurt am Main, DE
• Alexander Schiffer · Frankfurt am Main, DE
• Joseph T. Kim · Bound Brook, US
• Hans-Peter Nestler · Kelkheim, DE
• Mark Drew · Bound Brook, US

Key dates

• Filing date: Jan 16, 2014
• Grant date: Jan 10, 2017
• Expiry date: Jan 16, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.